US clinical stage developer Immunitas Therapeutics today announced the appointment of Annalisa D’Andrea as its chief scientific officer (CSO).
Dr D’Andrea has more than 25 years of basic and translational research and development expertise in both large and small pharmaceutical and biotech settings. She brings to Immunitas a strong history of success in immunology therapeutic development, having led products from target selection through clinical evaluation.
Massachusetts-based Immunitas says that her expertise will accelerate the company’s pipeline of highly differentiated, antibody-based therapeutics, including lead candidate IMT-009 which is currently dosing in the clinic and the company’s second program, an antibody oligonucleotide conjugate designed to stimulate Toll like receptor 9. Dr D’Andrea has been an advisor for the company and served as acting CSO since September 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze